EFFICACY OF GIKM (GLUCOSE, INSULIN, POTASSIUM, MAGNESIUM) THERAPY IN THE MANAGEMENT OF MYOCARDIAL INFARCTION COMPAIRED TO CURRENT THROMBOLYTIC THERAPY: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

• Main Authors: M GARAK YARAGHI, M KIANJOO, M MORTAZAVI, N SARRAFZADEGAN, H SHEMIRANI, M SHAHPARIAN
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2001-09-01
• Series: Journal of Research in Medical Sciences
• Subjects: Acute Myocardial Infarction, Coronary Artery Disease, Glucose, Insulin, Potassium,Magnesium, Thrombolytic therapy, Mortali1y, Morbidity, Double Blind Randomized Clinical Trial
• Online Access: http://journals.mui.ac.ir/jrms/article/view/3412

Introduction. Although common theraputic methods for myocardial infarction are conducted, mortality and morbidity of this disease are high, yet. Therefore, finding a new economical therapies such as metabolic modulation of ischemic myocardial muscle with thrombolytic therapy can somehow improves this situation. This study investigates the effect of glucose, insulin, potassium (GIK) and Magnasium (Mg) along with thrombolytic therapy on such patients.
 Methods. In this double blind randomized clinical trial study, two hundred patients, with myocardial infarction who have thrombolytic therapy indication, were randomly selected and divided into 6 groups of 30. Each group were treated based on their specific treatment protocol. Finally, people in the first five groups were compared with the sixth group about mortality and morbidity both in hospital and during 3 and 6 months after their treatment.Results were statistically analysed based on the questionares.
 Results. The patients aged from 58.77±2.6. From these people 77 percent were men. Heart failure and in hospital arrhythmia and ejection fraction of the people at the time of discharge in the five groups which recived metabolic intervention in same way were had better conclusion than the control group. In-hospital mortality and morbidity was not significantly different in any of the groups. Three month later, mortality and morbidity of the group who received GIK and Mg was significantly less than the control group. After six month none of the patients who received high dose GIK and Mg along with thrombolytic therapy, died, while at the same time the rate of death in the control group was 44.4 percent.
 Discussion. The results showed that GIK infusion and Mg along with thrombolytic therapy can significantly decrease the mortality and morbidity of the patients with myocardial infarction either in hospital or after a long time.